产品/疗法

Obecabtagene Autoleucel 治疗复发/难治性 B-ALL：临床疗效与安全性的批判性综述

Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety.

尽管物流复杂性和高昂的获取成本仍是 CAR-T 细胞疗法的可及性障碍，obe-cel 的分子设计和安全性特征代表了 R/R B-ALL 患者治疗领域的重大进步。

勘误：“肿瘤负荷指导的给药有助于减轻复发/难治性 B 细胞急性淋巴细胞白血病成年患者接受 obecabtagene autoleucel 治疗后的免疫毒性”

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patien

obecabtagene autoleucel 与外部对照臂在复发/难治性 B 细胞急性淋巴细胞白血病成人患者中的比较

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

CAR-T 细胞治疗后的免疫效应细胞相关血液毒性：来自大型国家数据库的见解

Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.

FELIX 研究中接受 Obecabtagene Autoleucel 治疗的复发/难治性 B 细胞急性淋巴细胞白血病成人患者 CAR-T 细胞动力学、持久性与临床结局

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in

肿瘤负荷指导的给药有助于减轻成人复发/难治性 B 细胞急性淋巴细胞白血病患者 obecabtagene autoleucel 治疗后的免疫毒性

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relap

变革急性淋巴细胞白血病治疗：双特异性抗体、抗体药物偶联物与 CAR-T 细胞疗法的作用

Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy.

obecabtagene autoleucel：用于复发/难治性 B 细胞急性淋巴细胞白血病的新型 CD19 靶向 CAR-T 细胞疗法——降低毒性与 T 细胞耗竭的未来？

Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing

obe-cel 代表了 CAR-T 细胞治疗的重要概念进步，为现有的高亲和力 CD19 CAR 提供了一种有前景的替代方案。动力学受体工程与分次给药方案的整合似乎增强了安全性和缓解持久性，可能重新定义 R/R B-ALL 的治疗目标。随着真实世界经验和更长期数据的积累，obe-cel 可能不仅作为移植桥接，还可成为特定患者的确定性治疗。这一方法的成功可能为未来跨血液恶性肿瘤的 CAR 设计提供参考，并支持向受体调谐细胞免疫治疗的范式转变

Obecabtagene Autoleucel 治疗 B 细胞急性淋巴细胞白血病

Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia.

中等亲和力 CD19 靶向 CAR-T 细胞产品 obecabtagene autoleucel 在 R/R B-ALL 中显示出良好的安全性与疗效

Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL.

B 系急性淋巴细胞白血病治疗中不断增多的免疫治疗

Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemia.

Obecabtagene Autoleucel：首次获批

Obecabtagene Autoleucel: First Approval.

成人 B 细胞急性淋巴细胞白血病一线免疫治疗联合策略：降低化疗强度与毒性并发挥疗效

Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harn

简讯：Obecabtagene autoleucel（Aucatzyl）——又一种用于 ALL 的 CAR-T 细胞免疫疗法

In brief: Obecabtagene autoleucel (Aucatzyl) - another CAR-T cell immunotherapy for ALL.

Obecabtagene autoleucel 治疗成人 B 细胞急性淋巴细胞白血病

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Obe-cel 在复发/难治性 B 细胞急性淋巴细胞白血病成人患者中产生了高比例的持久缓解，且 3 级或以上免疫相关毒性反应的发生率较低。

Brexucabtagene Autoleucel 治疗复发/难治性 B 细胞急性淋巴细胞白血病患者的临床洞见

Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.